Who Exports Cabazitaxel from India — 59 Suppliers Behind a $9.2M Market
India's cabazitaxel export market is supplied by 59 active exporters who collectively shipped $9.2M across 307 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 38.4% market share, followed by MSN LABORATORIES PRIVATE LIMITED and DR REDDY S LABORATORIES LIMITED. The top 5 suppliers together control 69.7% of total export value, reflecting a concentrated market structure.
Top Cabazitaxel Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading cabazitaxel exporter from India, holding a 38.4% share of the $9.2M market across 307 shipments from 59 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, MSN LABORATORIES PRIVATE LIMITED, DR REDDY S LABORATORIES LIMITED, DR REDDYS LABORATORIES LIMITED, INTAS PHARMACEUTICALS LTD — collectively control 69.7% of total export value, indicating a moderately concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (38.4%), MSN LABORATORIES PRIVATE LIMITED (17.0%), DR REDDY S LABORATORIES LIMITED (5.7%), DR REDDYS LABORATORIES LIMITED (5.7%), INTAS PHARMACEUTICALS LTD (3.0%).
Top Cabazitaxel Exporters from India
Ranked by export value · 59 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED PHARMA DRUGS & MEDI CABAZITAXEL 20MG/MLPHARMA DRUG&MED:CABAZITAXEL 20MG/ML 3ML(CABAZITAXEL DR. REDDY'S 60MG/1.5ML1S IT | $3.5M | 9 | 38.4% |
| 2 | MSN LABORATORIES PRIVATE LIMITED PHARMA DRUGS & MEDI CABAZITAXEL 20MG/MLXATIZA 60 -CL )PHARMA DRUG&MED: CABAZITAXEL 20MG/ML 3ML | $1.6M | 8 | 17.0% |
| 3 | DR REDDY S LABORATORIES LIMITED CABAZITAXEL DR. REDDY'S 60MG/1.5ML1S ITPHARMA DRUG&MED:CABAZITAXEL 20MG/ML 3ML(PHR DRUGS&MEDI CABAZITAXEL 20MG/ML 3ML(A | $524.0K | 3 | 5.7% |
| 4 | DR REDDYS LABORATORIES LIMITED CABAZITAXEL DR. REDDY'S 60MG/1.5ML1S ITPHARMA DRUG&MED:CABAZITAXEL 20MG/ML 3ML(PHR DRUGS&MEDI CABAZITAXEL 20MG/ML 3ML(A | $523.6K | 3 | 5.7% |
| 5 | INTAS PHARMACEUTICALS LTD PHARMA DRUGS & MEDI CABAZITAXEL 20MG/MLPHARMA DRUG&MED:CABAZITAXEL 20MG/ML 3ML(CABAZITAXEL DR. REDDY'S 60MG/1.5ML1S IT | $273.9K | 3 | 3.0% |
| 6 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED CABAZITAXEL INJ 60MG 1 5ML Z TEXEL 31 VIAL AS A FREE SAMPLE | $203.3K | 1 | 2.2% |
| 7 | BETA DRUGS LIMITED | $23.7K | 1 | 0.3% |
| 8 | GNH INDIA PHARMACEUTICALS LIMITED | $23.5K | 2 | 0.3% |
| 9 | ONCOHEAL HEALTHCARE LLP | $23.1K | 2 | 0.2% |
| 10 | R.S. SURGIPHARM PRIVATE LIMITED | $23.0K | 1 | 0.2% |
| 11 | ASPIRA BIOHEALTH LLP | $7.5K | 1 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Cabazitaxel exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter, July 2023 | Yes, April 2007 | Yes | Not verified | Received FDA warning letters in July and November 2023 for CGMP violations; WHO- |
| Dr. Reddy's Laboratories Limited | Approved | Yes | Yes | 89 | Holds FDA approvals and WHO-GMP certification; has 89 approved ANDAs. |
TransData Nexus reviewed the regulatory standing of 2 leading Cabazitaxel exporters from India. 1 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 2 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Cabazitaxel sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts numerous pharmaceutical companies specializing in active pharmaceutical ingredients (APIs) and bulk drugs. Notable firms include A.R. Life Sciences, which manufactures a wide range of APIs for treatments such as cardiovascular diseases and leukemia. Additionally, Hyderabad's Pharma City project has been recognized as a National Investment Manufacturing Zone, further solidifying its status as a pharmaceutical hub.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations and contract manufacturing capabilities. Vadodara, in particular, is home to companies like Wellmed Pharma, which offers a comprehensive range of pharmaceutical products, including tablets, ointments, and injectables. The region's focus on formulations makes it a strategic location for sourcing finished pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. Companies like Formel Labs have manufacturing facilities in Mumbai, emphasizing the region's role in pharmaceutical production and export. The proximity to international shipping routes enhances the efficiency of exporting pharmaceuticals from this cluster.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, primarily due to favorable tax incentives. This zone attracts numerous pharmaceutical companies seeking cost-effective production solutions. The region's infrastructure supports large-scale manufacturing, making it a viable option for companies looking to optimize production costs.
5Sourcing Recommendations
- Diversify Supplier Base: While INTAS PHARMACEUTICALS LIMITED and MSN LABORATORIES PRIVATE LIMITED are leading suppliers, consider engaging with other manufacturers in Hyderabad and Gujarat to mitigate supply chain risks.
- Leverage Export Infrastructure: Utilize the export capabilities of the Mumbai-Thane-Raigad region to streamline logistics and reduce lead times for international shipments.
- Explore Tax Incentives: Assess the benefits of sourcing from the Baddi-Nalagarh region to take advantage of tax incentives and potentially lower production costs.
- Monitor Regulatory Compliance: Ensure that all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Cabazitaxel exporters from India
Dr. Reddy's Laboratories Limited — Senores Pharma acquires 14 ANDAs from Dr. Reddy's
Dr. Reddy's Laboratories divested a portfolio of 14 Abbreviated New Drug Applications (ANDAs) to Senores Pharmaceuticals. This portfolio included 13 approved ANDAs and one pending approval. - IMPACT: This divestiture is not expected to directly impact Dr. Reddy's Cabazitaxel exports, as the ANDAs involved pertain to different products.
Impact: This divestiture is not expected to directly impact Dr. Reddy's Cabazitaxel exports, as the ANDAs involved pertain to different products.
Dr. Reddy's Laboratories Limited — Dr. Reddy's acquires Nimbus Health GmbH
Dr. Reddy's Laboratories acquired Nimbus Health GmbH, a German pharmaceutical wholesaler specializing in medical cannabis. - IMPACT: This acquisition is unlikely to affect Dr. Reddy's Cabazitaxel exports, as it focuses on expanding the company's presence in the medical cannabis market.
Impact: This acquisition is unlikely to affect Dr. Reddy's Cabazitaxel exports, as it focuses on expanding the company's presence in the medical cannabis market.
Dr. Reddy's Laboratories Limited — Dr. Reddy's acquires India trademarks for two HRT drugs
Dr. Reddy's Laboratories acquired the India trademarks for specialty brands Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited for $32.15 million, strengthening its gynecology portfolio in India. - IMPACT: This acquisition is not expected to impact Dr. Reddy's Cabazitaxel exports, as it pertains to hormone replacement therapy drugs within the Indian market.
Impact: This acquisition is not expected to impact Dr. Reddy's Cabazitaxel exports, as it pertains to hormone replacement therapy drugs within the Indian market.
Common Questions — Cabazitaxel Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which cabazitaxel supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 108 recorded shipments worth $3.5M. MSN LABORATORIES PRIVATE LIMITED (37 shipments) and DR REDDY S LABORATORIES LIMITED (3 shipments) are also established high-volume exporters.
Q How many cabazitaxel manufacturers are there in India?
India has 59 active cabazitaxel exporters with a combined export market of $9.2M across 307 shipments to 49 countries. The top 5 suppliers hold 69.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for cabazitaxel from India?
Average FOB unit price: $123.65 per unit, ranging from $0.08 to $2237.14. Average shipment value: $30.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 59 verified Indian exporters of Cabazitaxel ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 307 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 49 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
307 Verified Shipments
59 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists